Drug-drug interactions of silymarin on the perspective of pharmacokinetics

Journal of Ethnopharmacology

Volumn 121, Issue 2, 2009, Pages 185-193

  Wu, Jhy Wen ^a,b   Lin, Lie Chwen ^b,c   Tsai, Tung Hu ^b,d  

^a CENTER FOR DISEASE CONTROL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

^d TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

Drug drug interaction; Milk thistle; Pharmacokinetics; Silymarin

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450; DIGOXIN; FLAVONOID; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P; INDINAVIR; IRINOTECAN; ISOSILYBIN A; ISOSILYBIN B; METRONIDAZOLE; NIFEDIPINE; PHENOL DERIVATIVE; PLANT MEDICINAL PRODUCT; PYRAZINAMIDE; QUINIDINE; RANITIDINE; RIFAMPICIN; ROSUVASTATIN; SILIBININ; SILIBININ PHOSPHATIDYLCHOLINE COMPLEX; SILICRISTIN; SILIDIANIN; SILIPHOS; SILYCHRISTIN A; SILYCHRISTIN B; SILYMARIN; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE; VERAPAMIL;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; BILIARY EXCRETION; CELL PROTECTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; HUMAN; IN VIVO STUDY; LIVER PROTECTION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; REVIEW; SILYBUM MARIANUM; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; URINARY EXCRETION;

ANIMALS; BIOLOGICAL TRANSPORT; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; GLUCURONOSYLTRANSFERASE; HUMANS; MILK THISTLE; P-GLYCOPROTEIN; SILYMARIN;

SILYBUM MARIANUM;

EID: 57949097025     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2008.10.036     Document Type: Review

References (115)

1. Arcari M., Brambilla A., Brandt A., Caponi R., Corsi G., Di Rella M., Solinas F., and Wachter W.P. A new inclusion complex of silibinin and beta-cyclodextrins: in vitro dissolution kinetics and in vivo absorption in comparison with traditional formulations. Bollettino Chimico Farmaceutico 131 (1992) 205-209
2. Barzaghi N., Crema F., Gatti G., Pifferi G., and Perucca E. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. European Journal of Drug Metabolism and Pharmacokinetics 15 (1990) 333-338
3. Beckmann-Knopp S., Rietbrock S., Weyhenmeyer R., Bocker R.H., Beckurts K.T., Lang W., Hunz M., and Fuhr U. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacology & Toxicology 86 (2000) 250-256
4. Borst P., Evers R., Kool M., and Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. Journal of the National Cancer Institute 92 (2000) 1295-1302
5. Campos R., Garrido A., Guerra R., and Valenzuela A. Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver. Planta Medica 55 (1989) 417-419
6. Carini R., Comoglio A., Albano E., and Poli G. Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by the silybin-phospholipid complex IdB 1016. Biochemical Pharmacology 43 (1992) 2111-2115
7. Cavet M.E., West M., and Simmons N.L. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. British Journal of Pharmacology 118 (1996) 1389-1396
8. Chen C.J., Chin J.E., Ueda K., Clark D.P., Pastan I., Gottesman M.M., and Roninson I.B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47 (1986) 381-389
9. Chrungoo V.J., Singh K., and Singh J. Silymarin mediated differential modulation of toxicity induced by carbon tetrachloride, paracetamol and D-galactosamine in freshly isolated rat hepatocytes. Indian Journal of Experimental Biology 35 (1997) 611-617
10. Chu X.Y., Kato Y., and Sugiyama Y. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats. Drug Metabolism and Disposition 27 (1999) 440-441
11. Chu X.Y., Suzuki H., Ueda K., Kato Y., Akiyama S., and Sugiyama Y. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. The Journal of Pharmacology and Experimental Therapeutics 288 (1999) 735-741
12. D'Andrea V., Perez L.M., and Sanchez Pozzi E.J. Inhibition of rat liver UDP-glucuronosyltransferase by silymarin and the metabolite silibinin-glucuronide. Life Sciences 77 (2005) 683-692
13. Danks M.K., Morton C.L., Krull E.J., Cheshire P.J., Richmond L.B., Naeve C.W., Pawlik C.A., Houghton P.J., and Potter P.M. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clinical Cancer Research 5 (1999) 917-924
14. Dehmlow C., Erhard J., and de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 23 (1996) 749-754
15. Deng J.W., Shon J.H., Shin H.J., Park S.J., Yeo C.W., Zhou H.H., Song I.S., and Shin J.G. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. Pharmaceutical Research 25 (2008) 1807-1814
16. DerMarderosian A., and Beutler J.A. The Review of Natural Products: The Most Complete Source of Natural Product Information (2005), Facts & Comparisons, Saint Louis, Mo
17. DiCenzo R., Shelton M., Jordan K., Koval C., Forrest A., Reichman R., and Morse G. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 23 (2003) 866-870
18. Dvorak Z., Kosina P., Walterova D., Simanek V., Bachleda P., and Ulrichova J. Primary cultures of human hepatocytes as a tool in cytotoxicity studies: cell protection against model toxins by flavonolignans obtained from Silybum marianum. Toxicology Letters 137 (2003) 201-212
19. Favari L., and Perez-Alvarez V. Comparative effects of colchicine and silymarin on CCl4-chronic liver damage in rats. Archives of Medical Research 28 (1997) 11-17
20. Ferenci P., Dragosics B., Dittrich H., Frank H., Benda L., Lochs H., Meryn S., Base W., and Schneider B. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. Journal of Hepatology 9 (1989) 105-113
21. Filburn C.R., Kettenacker R., and Griffin D.W. Bioavailability of a silybin-phosphatidylcholine complex in dogs. Journal of Veterinary Pharmacology and Therapeutics 30 (2007) 132-138
22. Flora K., Hahn M., Rosen H., and Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. The American Journal of Gastroenterology 93 (1998) 139-143
23. Flory P.J., Krug G., Lorenz D., and Mennicke W.H. [Studies on elimination of silymarin in cholecystectomized patients. I. Biliary and renal elimination after a single oral dose]. Planta Medica 38 (1980) 227-237
24. Fuhr U., Beckmann-Knopp S., Jetter A., Luck H., and Mengs U. The effect of silymarin on oral nifedipine pharmacokinetics. Planta Medica 73 (2007) 1429-1435
25. Funaki T., Soons P.A., Guengerich F.P., and Breimer D.D. In vivo oxidative cleavage of a pyridine-carboxylic acid ester metabolite of nifedipine. Biochemical Pharmacology 38 (1989) 4213-4216
26. Gatti G., and Perucca E. Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics 32 (1994) 614-617
27. Gazak R., Walterova D., and Kren V. Silybin and silymarin-new and emerging applications in medicine. Current Medicinal Chemistry 14 (2007) 315-338
28. Gower J.D., Fuller B.J., and Green C.J. Prevention by antioxidants of oxidative damage to rabbit kidneys subjected to cold ischaemia. Biochemical Pharmacology 38 (1989) 213-215
29. Gunaratna C., and Zhang T. Application of liquid chromatography-electrospray ionization-ion trap mass spectrometry to investigate the metabolism of silibinin in human liver microsomes. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 794 (2003) 303-310
30. Gurley B.J., Barone G.W., Williams D.K., Carrier J., Breen P., Yates C.R., Song P.F., Hubbard M.A., Tong Y., and Cheboyina S. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metabolism and Disposition 34 (2006) 69-74
31. Gurley B.J., Gardner S.F., Hubbard M.A., Williams D.K., Gentry W.B., Carrier J., Khan I.A., Edwards D.J., and Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clinical Pharmacology and Therapeutics 76 (2004) 428-440
32. Han Y.H., Lou H.X., Ren D.M., Sun L.R., Ma B., and Ji M. Stereoselective metabolism of silybin diastereoisomers in the glucuronidation process. Journal of Pharmaceutical and Biomedical Analysis 34 (2004) 1071-1078
33. Hoh C., Boocock D., Marczylo T., Singh R., Berry D.P., Dennison A.R., Hemingway D., Miller A., West K., Euden S., Garcea G., Farmer P.B., Steward W.P., and Gescher A.J. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clinical Cancer Research 12 (2006) 2944-2950
34. Hoh C.S., Boocock D.J., Marczylo T.H., Brown V.A., Cai H., Steward W.P., Berry D.P., and Gescher A.J. Quantitation of silibinin, a putative cancer chemopreventive agent derived from milk thistle (Silybum marianum), in human plasma by high-performance liquid chromatography and identification of possible metabolites. Journal of Agricultural and Food Chemistry 55 (2007) 2532-2535
35. Hruby K., Csomos G., Fuhrmann M., and Thaler H. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Human Toxicology 2 (1983) 183-195
36. Jancova P., Anzenbacherova E., Papouskova B., Lemr K., Luzna P., Veinlichova A., Anzenbacher P., and Simanek V. Silybin is metabolized by cytochrome P450 2C8 in vitro. Drug Metabolism and Disposition 35 (2007) 2035-2039
37. Johnson V.J., He Q., Osuchowski M.F., and Sharma R.P. Physiological responses of a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: III. Silymarin inhibits T-lymphocyte function at low doses but stimulates inflammatory processes at high doses. Planta Medica 69 (2003) 44-49
38. Katiyar S.K. Silymarin and skin cancer prevention: anti-inflammatory, antioxidant and immunomodulatory effects (Review). International Journal of Oncology 26 (2005) 169-176
39. Katiyar S.K., Korman N.J., Mukhtar H., and Agarwal R. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. Journal of the National Cancer Institute 89 (1997) 556-566
40. Kaufman D.W., Kelly J.P., Rosenberg L., Anderson T.E., and Mitchell A.A. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. Journal of the American Medical Association 287 (2002) 337-344
41. Kaur M., and Agarwal R. Silymarin and epithelial cancer chemoprevention: how close we are to bedside?. Toxicology and Applied Pharmacology 224 (2007) 350-359
42. Kidd P., and Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). Alternative Medicine Review 10 (2005) 193-203
43. Kim Y.C., Kim E.J., Lee E.D., Kim J.H., Jang S.W., Kim Y.G., Kwon J.W., Kim W.B., and Lee M.G. Comparative bioavailability of silibinin in healthy male volunteers. International Journal of Clinical Pharmacology and Therapeutics 41 (2003) 593-596
44. Kleinbloesem C.H., van Brummelen P., van de Linde J.A., Voogd P.J., and Breimer D.D. Nifedipine: kinetics and dynamics in healthy subjects. Clinical Pharmacology and Therapeutics 35 (1984) 742-749
45. Kolars J.C., Schmiedlin-Ren P., Schuetz J.D., Fang C., and Watkins P.B. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. Journal of Clinical Investigation 90 (1992) 1871-1878
46. Kosina P., Maurel P., Ulrichova J., and Dvorak Z. Effect of silybin and its glycosides on the expression of cytochromes P450 1A2 and 3A4 in primary cultures of human hepatocytes. Journal of Biochemical and Molecular Toxicology 19 (2005) 149-153
47. Kren V., Ulrichova J., Kosina P., Stevenson D., Sedmera P., Prikrylova V., Halada P., and Simanek V. Chemoenzymatic preparation of silybin beta-glucuronides and their biological evaluation. Drug Metabolism and Disposition 28 (2000) 1513-1517
48. Kunimoto D., Warman A., Beckon A., Doering D., and Melenka L. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity. Clinical Infectious Diseases 36 (2003) e158-161
49. Lee J.I., Narayan M., and Barrett J.S. Analysis and comparison of active constituents in commercial standardized silymarin extracts by liquid chromatography-electrospray ionization mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 845 (2007) 95-103
50. Letteron P., Labbe G., Degott C., Berson A., Fromenty B., Delaforge M., Larrey D., and Pessayre D. Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant. Biochemical Pharmacology 39 (1990) 2027-2034
51. Li W., Gao J., Zhao H.Z., and Liu C.X. Development of a HPLC-UV assay for silybin-phosphatidylcholine complex (silybinin capsules) and its pharmacokinetic study in healthy male Chinese volunteers. European Journal of Drug Metabolism and Pharmacokinetics 31 (2006) 265-270
52. Lin J.H. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Advanced Drug Delivery Reviews 55 (2003) 53-81
53. Lin J.H., Chiba M., Chen I.W., Nishime J.A., deLuna F.A., Yamazaki M., and Lin Y.J. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 3A [correction of P-450 A] and p-glycoprotein induction. Drug Metabolism and Disposition 27 (1999) 1187-1193
54. Loft S., Otton S.V., Lennard M.S., Tucker G.T., and Poulsen H.E. Characterization of metronidazole metabolism by human liver microsomes. Biochemical Pharmacology 41 (1991) 1127-1134
55. Lorenz D., Lucker P.W., Mennicke W.H., and Wetzelsberger N. Pharmacokinetic studies with silymarin in human serum and bile. Methods and Findings in Experimental and Clinical Pharmacology 6 (1984) 655-661
56. Luper S. A review of plants used in the treatment of liver disease: part 1. Alternative Medicine Review 3 (1998) 410-421
57. Mansour H.H., Hafez H.F., and Fahmy N.M. Silymarin modulates cisplatin-induced oxidative stress and hepatotoxicity in rats. Journal of Biochemistry and Molecular Biology 39 (2006) 656-661
58. Mascher H., Kikuta C., and Weyhenmeyer R. Diastereomeric separation of free and conjugated silibinin in plasma by reversed phase HPLC after specific extraction. Journal of Liquid Chromatography 16 (1993) 2777-2789
59. Mereish K.A., Bunner D.L., Ragland D.R., and Creasia D.A. Protection against microcystin-LR-induced hepatotoxicity by silymarin: biochemistry, histopathology, and lethality. Pharmaceutical Research 8 (1991) 273-277
60. Mills E., Wilson K., Clarke M., Foster B., Walker S., Rachlis B., DeGroot N., Montori V.M., Gold W., Phillips E., Myers S., and Gallicano K. Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. European Journal of Clinical Pharmacology 61 (2005) 1-7
61. Morazzoni P., and Bombardelli E. Silybum marianum (fitoterapia). Fitoterapia 66 (1995) 3-42
62. Morazzoni P., Montalbetti A., Malandrino S., and Pifferi G. Comparative pharmacokinetics of silipide and silymarin in rats. European Journal of Drug Metabolism and Pharmacokinetics 18 (1993) 289-297
63. Mourelle M., Favari L., and Amezcua J.L. Protection against thallium hepatotoxicity by silymarin. Journal of Applied Toxicology 8 (1988) 351-354
64. Mourelle M., and Franco M.T. Erythrocyte defects precede the onset of CCl4-induced liver cirrhosis. Protection by silymarin. Life Sciences 48 (1991) 1083-1090
65. Muriel P., Garciapina T., Perez-Alvarez V., and Mourelle M. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. Journal of Applied Toxicology 12 (1992) 439-442
66. Muriel P., and Mourelle M. Prevention by silymarin of membrane alterations in acute CCl4 liver damage. Journal of Applied Toxicology 10 (1990) 275-279
67. Nencini C., Giorgi G., and Micheli L. Protective effect of silymarin on oxidative stress in rat brain. Phytomedicine 14 (2007) 129-135
68. Ohno Y., Hisaka A., and Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clinical Pharmacokinetics 46 (2007) 681-696
69. Pal D., and Mitra A.K. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sciences 78 (2006) 2131-2145
70. Patel J., Buddha B., Dey S., Pal D., and Mitra A.K. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. American Journal of Therapeutics 11 (2004) 262-277
71. Peden N.R., Richards D.A., Saunders J.H., and Wormsley K.G. Pharmacologically effective plasma concentrations of ranitidine. Lancet 28 (1979) 199-200
72. Piscitelli S.C., Formentini E., Burstein A.H., Alfaro R., Jagannatha S., and Falloon J. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 22 (2002) 551-556
73. Post-White J., Ladas E.J., and Kelly K.M. Advances in the use of milk thistle (Silybum marianum). Integrative Cancer Therapies 6 (2007) 104-109
74. Rajnarayana K., Reddy M.S., Vidyasagar J., and Krishna D.R. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung 54 (2004) 109-113
75. Rao B.N., Srinivas M., Kumar Y.S., and Rao Y.M. Effect of silymarin on the oral bioavailability of ranitidine in healthy human volunteers. Drug Metabolism and Drug Interactions 22 (2007) 175-185
76. Rickling B., Hans B., Kramarczyk R., Krumbiegel G., and Weyhenmeyer R. Two high-performance liquid chromatographic assays for the determination of free and total silibinin diastereomers in plasma using column switching with electrochemical detection and reversed-phase chromatography with ultraviolet detection. Journal of Chromatography. B, Biomedical Applications 670 (1995) 267-277
77. Saller R., Meier R., and Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 61 (2001) 2035-2063
78. Salphati L., and Benet L.Z. Metabolism of digoxin and digoxigenin digitoxosides in rat liver microsomes: involvement of cytochrome P4503A. Xenobiotica 29 (1999) 171-185
79. Santos A., Zanetta S., Cresteil T., Deroussent A., Pein F., Raymond E., Vernillet L., Risse M.L., Boige V., Gouyette A., and Vassal G. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clinical Cancer Research 6 (2000) 2012-2020
80. Schandalik R., and Perucca E. Pharmacokinetics of silybin following oral administration of silipide in patients with extrahepatic biliary obstruction. Drugs under Experimental and Clinical Research 20 (1994) 37-42
81. Schinkel A.H. The physiological function of drug-transporting P-glycoproteins. Seminars in Cancer Biology 8 (1997) 161-170
82. Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A., and Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. Journal of Clinical Investigation 96 (1995) 1698-1705
83. Schriewer H., and Lohmann J. [Disturbances in the regulation of phospholipid metabolism of the whole liver, mitochondria and microsomes in acute thioacetamide poisoning and the influence of silymarin]. Arzneimittelforschung 26 (1976) 65-69
84. Shimada T., Yamazaki H., Mimura M., Inui Y., and Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. The Journal of Pharmacology and Experimental Therapeutics 270 (1994) 414-423
85. Singh J., Arora A., Garg P.K., Thakur V.S., Pande J.N., and Tandon R.K. Antituberculosis treatment-induced hepatotoxicity: role of predictive factors. Postgraduate Medical Journal 71 (1995) 359-362
86. Slichenmyer W.J., Rowinsky E.K., Donehower R.C., and Kaufmann S.H. The current status of camptothecin analogues as antitumor agents. Journal of the National Cancer Institute 85 (1993) 271-291
87. Sridar C., Goosen T.C., Kent U.M., Williams J.A., and Hollenberg P.F. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metabolism and Disposition 32 (2004) 587-594
88. Stone P.H., Antman E.M., Muller J.E., and Braunwald E. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications. Annals of Internal Medicine 93 (1980) 886-904
89. Su S.F., and Huang J.D. Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metabolism and Disposition 24 (1996) 142-147
90. Svagera Z., Skottova N., Vana P., Vecera R., Urbanek K., Belejova M., Kosina P., and Simanek V. Plasma lipoproteins in transport of silibinin, an antioxidant flavonolignan from Silybum marianum. Phytotherapy Research 17 (2003) 524-530
91. Tally F.P., Goldin B.R., Sullivan N., Johnston J., and Gorbach S.L. Antimicrobial activity of metronidazole in anaerobic bacteria. Antimicrobial Agents and Chemotherapy 13 (1978) 460-465
92. Toklu H.Z., Tunali-Akbay T., Erkanli G., Yuksel M., Ercan F., and Sener G. Silymarin, the antioxidant component of Silybum marianum, protects against burn-induced oxidative skin injury. Burns 33 (2007) 908-916
93. Trnka L., Kuska J., and Havel A. Comparison of the antituberculous activity of morphazinamide and pyrazinamide on chronic experimental tuberculosis. I. The antimycobacterial efficacy made in vitro and in vivo. Chemotherapy 9 (1964) 158-167
94. Valenzuela A., Lagos C., Schmidt K., and Videla L.A. Silymarin protection against hepatic lipid peroxidation induced by acute ethanol intoxication in the rat. Biochemical Pharmacology 34 (1985) 2209-2212
95. van Erp N.P., Baker S.D., Zhao M., Rudek M.A., Guchelaar H.J., Nortier J.W., Sparreboom A., and Gelderblom H. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clinical Cancer Research 11 (2005) 7800-7806
96. Venkataramanan R., Komoroski B., and Strom S. In vitro and in vivo assessment of herb drug interactions. Life Sciences 78 (2006) 2105-2115
97. Venkataramanan R., Ramachandran V., Komoroski B.J., Zhang S., Schiff P.L., and Strom S.C. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metabolism and Disposition 28 (2000) 1270-1273
98. Vidt D.G., Cressman M.D., Harris S., Pears J.S., and Hutchinson H.G. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 102 (2004) 52-60
99. Vogel G., Tuchweber B., Trost W., and Mengs U. Protection by silibinin against Amanita phalloides intoxication in beagles. Toxicology and Applied Pharmacology 73 (1984) 355-362
100. von Schonfeld J., Weisbrod B., and Muller M.K. Silibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin A toxicity. Cellular and Molecular Life Sciences 53 (1997) 917-920
101. Watkins P.B., Wrighton S.A., Maurel P., Schuetz E.G., Mendez-Picon G., Parker G.A., and Guzelian P.S. Identification of an inducible form of cytochrome P-450 in human liver. Proceedings of the National Academy of Sciences of the United States of America 82 (1985) 6310-6314
102. Watkins P.B., Wrighton S.A., Schuetz E.G., Molowa D.T., and Guzelian P.S. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. Journal of Clinical Investigation 80 (1987) 1029-1036
103. Wellington K., and Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 15 (2001) 465-489
104. Wen, Z., Dumas, T.E., Schrieber, S.J., Hawke, R.L., Fried, M.W., Smith, P.C., 2007. Pharmacokinetics and metabolic profile of free, conjugated and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metabolism and Disposition.
105. Westphal K., Weinbrenner A., Giessmann T., Stuhr M., Franke G., Zschiesche M., Oertel R., Terhaag B., Kroemer H.K., and Siegmund W. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clinical Pharmacology and Therapeutics 68 (2000) 6-12
106. Weyhenmeyer R., Mascher H., and Birkmayer J. Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. International Journal of Clinical Pharmacology, Therapy, and Toxicology 30 (1992) 134-138
107. Wilkinson G.R. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. Journal of Pharmacokinetics and Biopharmaceutics 24 (1996) 475-490
108. Wu J.W., Lin L.C., Hung S.C., Chi C.W., and Tsai T.H. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. Journal of Pharmaceutical and Biomedical Analysis 45 (2007) 635-641
109. Wu J.W., Lin L.C., Hung S.C., Lin C.H., Chi C.W., and Tsai T.H. Hepatobiliary excretion of silibinin in normal and liver cirrhotic rats. Drug Metabolism and Disposition 36 (2008) 589-596
110. Wu J.W., and Tsai T.H. Effect of silibinin on the pharmacokinetics of pyrazinamide and pyrazinoic acid in rats. Drug Metabolism and Disposition 35 (2007) 1603-1610
111. Yao H.M., and Chiou W.L. The complexity of intestinal absorption and exsorption of digoxin in rats. International Journal of Pharmaceutics 322 (2006) 79-86
112. Yee D., Valiquette C., Pelletier M., Parisien I., Rocher I., and Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. American Journal of Respiratory and Critical Care Medicine 167 (2003) 1472-1477
113. Zhang S., and Morris M.E. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharmaceutical Research 20 (2003) 1184-1191
114. Zhao J., and Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis 20 (1999) 2101-2108
115. Zhao J., Lahiri-Chatterjee M., Sharma Y., and Agarwal R. Inhibitory effect of a flavonoid antioxidant silymarin on benzoyl peroxide-induced tumor promotion, oxidative stress and inflammatory responses in SENCAR mouse skin. Carcinogenesis 21 (2000) 811-816